TY - JOUR KW - Adolescent KW - Adult KW - Drug Administration Schedule KW - Female KW - Humans KW - Leprostatic Agents KW - leprosy KW - Male KW - Middle Aged KW - Recurrence KW - Time Factors KW - Young Adult AU - Fajardo TT AU - Villahermosa L AU - Pardillo FE AU - Abalos R AU - Burgos J AU - Dela Cruz E AU - Gelber R AB -

As a participant in a multicenter trial, we evaluated the relapse rate in 189 multibacillary (MB) leprosy patients treated with four different regimens and followed-up for as many as 12 years after the initiation of treatment. Treatment regimens included 1 year of WHO MDT (a regimen including dapsone, clofazimine, and rifampin), 2 years of WHO MDT, 1 month of daily rifampin and daily ofloxacin, and 1 year of WHO MDT plus an initial 1 month of daily rifampin and daily ofloxacin. Relapse rates after 9 and 12 years from the initiation of therapy in the three regimens that included WHO MDT were 0-3%, whereas relapses occurred in those treated with the 1-month regimen alone at a significantly greater rate (P < 0.05): 11% at 9 years and 25% at 12 years. Relapses occurred late, beginning at 5 years after the initiation of therapy, and were confined to those patients histopathologically borderline lepromatous and polar lepromatous having a high bacterial burden. Prospects for an alternative effective short-course therapy of leprosy are presented.

BT - The American journal of tropical medicine and hygiene C1 - http://www.ncbi.nlm.nih.gov/pubmed/19635893?dopt=Abstract CN - FAJARDO 2009 DA - 2009 Aug IS - 2 J2 - Am. J. Trop. Med. Hyg. LA - eng N2 -

As a participant in a multicenter trial, we evaluated the relapse rate in 189 multibacillary (MB) leprosy patients treated with four different regimens and followed-up for as many as 12 years after the initiation of treatment. Treatment regimens included 1 year of WHO MDT (a regimen including dapsone, clofazimine, and rifampin), 2 years of WHO MDT, 1 month of daily rifampin and daily ofloxacin, and 1 year of WHO MDT plus an initial 1 month of daily rifampin and daily ofloxacin. Relapse rates after 9 and 12 years from the initiation of therapy in the three regimens that included WHO MDT were 0-3%, whereas relapses occurred in those treated with the 1-month regimen alone at a significantly greater rate (P < 0.05): 11% at 9 years and 25% at 12 years. Relapses occurred late, beginning at 5 years after the initiation of therapy, and were confined to those patients histopathologically borderline lepromatous and polar lepromatous having a high bacterial burden. Prospects for an alternative effective short-course therapy of leprosy are presented.

PY - 2009 SP - 330 EP - 4 T2 - The American journal of tropical medicine and hygiene TI - A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens. UR - A Comparative Clinical Trial in Multibacillary Leprosy VL - 81 SN - 1476-1645 ER -